Current status: hormone substitution and risk of endometrial carcinoma
Kuhl, H.
Zentralblatt für Gynakologie 119(6): 296-297
1997
ISSN/ISBN: 0044-4197 PMID: 9312968 Document Number: 470449
Document emailed within 1 workday
Related Documents
Hausknecht, R.U.; Gusberg, S.B. 1969: Estrogen metabolism in patients at high risk for endometrial carcinoma. I. Urinary metabolites of H3-estradiol in normal postmenopausal women and those with endometrial carcinoma American Journal of Obstetrics and Gynecology 105(8): 1161-1167Senn, H.J. 1987: Current status of adjuvant chemo- and hormone therapy in resectable breast carcinoma Schweizerische Rundschau für Medizin Praxis 76(43): 1193-1199
Mangili, G.; De Marzi, P.; Viganò, R.; Rabaiotti, E.; Sassi, I.; Taccagni, G.L.; Garancini, P.; Frigerio, L. 2002: Identification of high risk patients with endometrial carcinoma. Prognostic assessment of endometrial cancer European Journal of Gynaecological Oncology 23(3): 216-220
Lauritzen, C. 1990: Colorectal carcinoma and substitution hormone treatment in menopause Zentralblatt für Gynakologie 112(23): 1493-1494
Van der Mooren, M.J.; Merkus, J.M. 1996: Favorable effects of menopausal hormone substitution therapy on risk factors for ischemic heart disease Nederlands Tijdschrift Voor Geneeskunde 140(25): 1328-1329
Tavani, A.; La Vecchia, C.; Brinton, L.A.; McTiernan, A. 2001: Hormone replacement therapy and risk of endometrial cancer Tumori 87(5): S20-S21
Cook, L.S.; Dong, Y.; Round, P.; Huang, X.; Magliocco, A.M.; Friedenreich, C.M. 2014: Hormone contraception before the first birth and endometrial cancer risk Cancer Epidemiology Biomarkers and Prevention: a Publication of the American Association for Cancer Research Cosponsored by the American Society of Preventive Oncology 23(2): 356-361
Kaiser, R.; Schulz, K.D. 1983: Current views on the epidemiology and etiology of endometrial carcinoma Der Gynakologe 16(2): 82-86
Eliassen, A.H.; Hankinson, S.E. 2008: Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies Advances in Experimental Medicine and Biology 630: 148-165
Magnusson, C.; Weiderpass, E. 2001: Hormone therapy in climacteric. Different effects of estrogen and gestagen on the risk of breast and endometrial cancer Lakartidningen 98(5): 418-421
Audet-Lapointe, P.; Ayoub, J.; Methot, Y. 1988: An innovative protocol, cyclic hormone-chemotherapy in the treatment of high-risk localized endometrial cancer Journal de Gynecologie Obstetrique et Biologie de la Reproduction 17(6): 751-755
Menon, P.S. 1992: Growth hormone therapy: current status Indian Pediatrics 29(7): 825-829
Zafran, N.; Levin, A.; Goldman, S.; Shalev, E. 2009: Progesterone receptor's profile and the effect of the hormone and its derivatives on invasiveness and MMP2 secretion in endometrial carcinoma cell lines Harefuah 148(7): 416-419; 477
Strnad, P. 1997: Hormone replacement and risk of breast carcinoma in a high-risk group of women Ceska Gynekologie 62(6): 355-361
Morack, G.; Ebeling, K.; Flach, W.; Peschel, H.G.; Pockrandt, H. 1984: Screening for endometrial carcinoma in a group at risk Archiv für Geschwulstforschung 54(5): 415-422
Chovanec, J.; Bienertová-Vasků, J.A.; Dostálová, Z.; Janků, M. 2007: Cholecystectomy--the risk factors for endometrial carcinoma? Ceska Gynekologie 72(6): 419-423
Yakata, M. 1982: Progress and the current status of steroid hormone assay Rinsho Byori. Japanese Journal of Clinical Pathology Suppl 52: 1-9
Salmi, T. 1980: Endometrial carcinoma risk factors, with special reference to the use of oestrogens Acta Endocrinologica. Supplementum 233: 37-43
Kudela, M.; Pilka, R. 2001: Is there a real risk in patients with endometrial carcinoma undergoing diagnostic hysteroscopy (HSC)? European Journal of Gynaecological Oncology 22(5): 342-344
Alvarez Rodríguez, S.; Alonso Gordoa, T.; Burgos Revilla, F.Javier. 2018: Current status of androgen deprivation therapy in hormone-sensitive prostate cancer Archivos Espanoles de Urologia 71(3): 247-257